Pincer Biotech appoints CEO, cementing goal to combat antibiotic resistance
The firm wants to develop treatments targeting certain types of antibiotic-resistant bacteria, and has recently brought in the founder of Expres2ion as chief executive, intensifying the firm’s work.
by albert rønning-andersson, translated by daniel pedersen
What are the most pressing medical challenges when it comes to developing new drugs against antimicrobial resistance (AMR)?
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
EMA publishes new plan to support antibiotic development
For subscribers
.jpg&w=384&q=75)
